The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
The Oncology Institute, Inc.NASDAQ: TOI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.62M fell 9.4% year over year, behind the +2.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -9.4% toward the trailing-twelve-month pace of +2.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 6.94M USD
- Year-over-year change
- +10.5%
- 4-year CAGR
- +20.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.94M | +10.5% |
| FY2024 | 2024-12-31 | 6.29M | +7.0% |
| FY2023 | 2023-12-31 | 5.87M | +33.1% |
| FY2022 | 2022-12-31 | 4.41M | +32.0% |
| FY2021 | 2021-12-31 | 3.34M | — |
Depreciation & Amortization vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.9% is the 8th highest of 10, against a peer median of +11.8%.
- Depreciation & amortization amounts to 1.2% of revenue for TOI, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | PEN 226.54M PEN | +4.8% | +17.2% | 5.0% |
| LTM Mar 2026 | $63.04M USD | +31.9% | +13.9% | 15.3% | |
| LTM Mar 2026 | $28.51M USD | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $21.79M USD | +14.1% | +17.5% | 9.0% | |
| LTM Mar 2026 | $15.69M USD | -11.0% | +10.1% | 1.6% | |
| LTM Mar 2026 | $13M USD | +24.1% | +9.8% | 14.0% | |
| LTM Mar 2026 | $9.28M USD | +53.3% | +32.9% | 3.1% | |
| LTM Mar 2026 | $9.13M USD | +1.8% | +70.1% | 4.4% | |
| LTM Mar 2026 | $6.78M USD | +2.9% | +16.3% | 1.2% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $1.25M USD | +3.0% | +39.2% | 1.3% |
| Peer median (excluding TOI) | — | +11.8% | +17.5% | 4.4% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.